Table 1.
Description of Included Trials
| Trial | No. of Patients Randomly Assigned | Inclusion Period | Median Follow-Up (years) | Histology | RT Total Dose (Gy) | No. of Fractions | Duration (weeks) | BED St/EXP | CT Dose | Patient Characteristic |
|---|---|---|---|---|---|---|---|---|---|---|
| ECOG 358824 | 417 | 1989-1992 | 13.0 | SCLC | Standard: 45 | 25 | 5 | 39.5 | Cisplatin 60 mg/m2 day 1 | PS 0-2 |
| Experimental: 45 | 30 | 3 BID | 43.9 | Etoposide 120 mg/m2 days 1-3 | ||||||
| 4 cycles (3 weeks) | ||||||||||
| NCCTG 89205225 | 268 | 1990-1996 | 9.3 | SCLC | Standard: 50.4 | 28 | 5.5 | 43.8 | Cisplatin 30 mg/m2 days 1-3 | PS 0-2 |
| Experimental: 48 | 32 | 5.5 SC* BID | 39.5 | Etoposide 130 mg/m2 days 1-3 | ||||||
| 6 cycles† (4 weeks) | ||||||||||
| RTOG 8808-ECOG 458826 | 326 | 1989-1992 | 6.8 | NSCLC | Standard: 60 Gy | 30 | 6 | 55.5 | None | KPS ≥ 70 |
| Experimental: 69.6 | 58 | 6 BID | 61.9 | Stage II-III | ||||||
| PMCI 88C09127 | 101 | 1989-1995 | Not reached | NSCLC | Standard: 60 | 30 | 6 | 55.5 | None | PS 0-1 |
| Experimental: 60 | 30 | 3 BID | 64.2 | Stage I-III | ||||||
| PMCI 88C091 CT27 | 107 | 1989-1995 | Not reached | NSCLC | Standard: 60 | 30 | 6 | 55.5 | Carboplatin 70 mg/m2 days 1-5 | PS 0-1 |
| Experimental: 60 | 30 | 3 BID | 64.2 | + Carboplatin 70 mg/m2 days 29-33 in standard arm | Stage I-III | |||||
| CHART28 | 563‡ | 1990-1995 | 6.9 | NSCLC | Standard: 60 | 30 | 6 | 55.5 | None | PS 0-1 |
| Experimental: 54 | 36 | 1.5 TID | 57.2 | Stage I-III | ||||||
| NCCTG 90245129 | 74 | 1992-1993 | 8.1 | NSCLC | Standard: 60 | 30 | 6 | 55.5 | None | PS 0-2 |
| Experimental: 60 | 40 | 6 SC§ BID | 52.5 | Stage III | ||||||
| NCCTG 94245230 | 246 | 1994-1999 | 7.3 | NSCLC | Standard: 60 | 30 | 6 | 55.5 | Cisplatin 30 mg/m2 days 1-3, 28-30 | PS 0-1 |
| Experimental: 60 | 40 | 6 SC§ BID | 52.5 | Etoposide 100 mg/m2 days 1-3, 28-30 | Stage III | |||||
| CHARTWEL31 | 300 | 1997-2005 | 4.9 | NSCLC | Standard: 66 | 33 | 6.5 | 60.6 | None | PS 0-1 |
| Experimental: 60 | 40 | 2.5 TID | 61.6 | Stage I-III | ||||||
| CHARTWEL CT31 | 106 | 1997-2005 | 3.5 | NSCLC | Standard: 66 | 33 | 6.5 | 60.6 | Induction CT—dependent on institution's choice | PS 0-1 |
| Experimental: 60 | 40 | 2.5 TID | 61.6 | Stage I-III | ||||||
| ECOG 259732 | 119 | 1998-2001 | 6.7 | NSCLC | Standard: 64 | 32 | 6.5 | 58.7 | Carboplatin AUC 6 day 1 | PS 0-1 |
| Experimental: 57.6 | 36 | 2.5 TID | 60.2 | Paclitaxel 225 mg/m2 day 1 | Stage III | |||||
| 2 cycles‖ (3 weeks) | ||||||||||
| Gliwice 200133 | 58 | 2001-2006 | 5.3 | NSCLC | Standard: 72 | 40 | 8 | 62.7 | None | PS 0-1 |
| Experimental: 72 | 40 | 5.5 | 68.5 | Stage II-III |
Abbreviations: BED, biologic effective dose; BID, RT given twice a day; CT, chemotherapy; if not specified, the chemotherapy is concomitant to the radiotherapy; CHART, Continuous Hyperfractionated Accelerated Radiation Therapy; CHARTWEL, CHART Week-End Less; ECOG, Eastern Cooperative Oncology Group; Exp, experimental; (K) PS, (Karnofsky) performance status; NCCTG, North Central Cancer Treatment Group; NSCLC, non–small-cell lung cancer; PCMI, Peter MacCallum Institute; RT, Radiotherapy; RTOG, Radiation Therapy Oncology Group; SC, split course; SCLC, small-cell lung cancer; St, standard; TID, RT given three times a day.
Two series of 8 days with a break of 2.5 weeks.
Three cycles induction, two cycles concomitant, and one after RT; etoposide dose was reduced to 100 mg/m2 for cycles 4 to 6.
Patients were randomly allocated in a 3:2 ratio to CHART or conventional radiotherapy.
Two series of 2 weeks with a break of 2 weeks.
Induction chemotherapy.